Cited by 287Cancer-related Molecular PathwaysEstrogen and related hormone effectsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

Bond, Gareth L., Hirshfield, Kim M., Kirchhoff, Tomas, Alexe, Gabriella, Bond, Elisabeth E., Robins, Harlan, Bartel, Frank, Taubert, Helge, Wuerl, Peter, Hait, William, Toppmeyer, Deborah, Offit, Kenneth, Levine, Arnold J.·2006·Cancer Research

DOI 10.1158/0008-5472.can-06-0180

Open this paper in CoChat — free account

Abstract

The importance of the p53 stress response pathway in the suppression of tumor formation is well documented. In a previous report, a single nucleotide polymorphism (SNP309 T/G) was found in the promoter of the MDM2 gene resulting in higher levels of MDM2 RNA and protein and, consequently, in the attenuation of the p53 pathway both in vitro and in vivo. As the SNP309 locus is found in a region of the MDM2 promoter, which is regulated by hormonal signaling pathways, and the G-allele of SNP309 increases the affinity of a well-described cotranscriptional activator of nuclear hormone receptors (i.e., Sp1), the hypothesis that the SNP309 locus could alter the effects of hormones on tumorigenesis was tested in vivo in humans. Data obtained from patients with three different sporadic cancers, from four independent case studies, support this hypothesis, providing an example for the genetic basis of gender differences in cancer and showing that the genotype at a specific locus can affect how hormones, like estrogen, affect tumorigenesis in humans.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-0180

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Cancer Epidemiology and Prevention
Schottenfeld, D. (2006) · doi:10.1093/acprof:oso/9780195149616.001.0001 · Cited by 3,376
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citation
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Li, C. I., Anderson, B. O., Daling, J. R., & Moe, R. E. (2003) · JAMA · doi:10.1001/jama.289.11.1421 · Cited by 579
Epidemiology of non-Hodgkin?s lymphoma (NHL): trends, geographic distribution, and etiology
M�ller, A. M. S., Ihorst, G., Mertelsmann, R. H., & Engelhardt, M. M. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0939-7 · Cited by 495
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer
Li, C. I. (2003) · JAMA · doi:10.1001/jama.289.24.3254 · Cited by 415
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310
Self-citation

Show all 50 references

Sorted by citations

Items 201–287 of 287

MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk
Knappskog, S., Gansmo, L. B., Romundstad, P., Bjørnslett, M., Trovik, J., Sommerfelt-Pettersen, J. K., Løkkevik, E., for the Norwegian Breast Cancer Group trial NBCG VI, Tollenaar, R. A. �. �., Seynaeve, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036263 · Cited by 11
Molecular Epidemiology of Female Lung Cancer
Yim, S., & Chung, Y. (2011) · Cancers · doi:10.3390/cancers3021861 · Cited by 11
TP53 Arg 72Pro and MDM2 SNP309 Polymorphisms and Colorectal Cancer Risk: A West Algerian Population Study
Abderrahmane, R., Louhibi, L., Moghtit, F. Z., Boubekeur, A., Benseddik, K., Boudjema, A., Benrrahal, F., Aberkane, M. S., Fodil, M., & Saïdi‐Mehtar, N. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9867-6 · Cited by 10
Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma
Wrench, D., Waters, R., Carlotti, E., Iqbal, S., Matthews, J., Calaminici, M., Gribben, J. G., Lister, T. A., & Fitzgibbon, J. (2008) · Haematologica · doi:10.3324/haematol.13533 · Cited by 10
Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
Nechushtan, H., Hamburger, T., Mendelson, S., Kadouri, L., Sharon, N. A., Pikarsky, E., & Peretz, T. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-60 · Cited by 10
Radiation-induced apoptosis varies among individuals and is modified by sex and age
Applebaum, M. A., Skol, A. D., Bond, E. E., Overholtzer, M., Bond, G. L., & Onel, K. (2014) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.925603 · Cited by 9
Self-citation
Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer
Khan, S. A., Idrees, K., Forslund, A., Zeng, Z., Rosenberg, S. M., Pinças, H., Barany, F., Offit, K., LaQuaglia, M. P., & Paty, P. B. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20996 · Cited by 9
Self-citation
Potential genotype-specific single nucleotide polymorphism interaction of common variation in p53 and its negative regulator mdm2 in cholangiocarcinoma susceptibility
Zimmer, V., Höblinger, A., Mihalache, F., Assmann, G., Acalovschi, M., & Lammert, F. (2012) · Oncology Letters · doi:10.3892/ol.2012.680 · Cited by 9
The transcription-independent mitochondrial cell death pathway is defective in non-transformed cells containing the Pro47Ser variant of p53
Budina-Kolomets, A., Barnoud, T., & Murphy, M. E. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1472194 · Cited by 9
Association of HDM2 Transcript Levels with Age of Onset and Prognosis in Soft Tissue Sarcomas
Taubert, H. W., Bartel, F., Greither, T., Bache, M., Kappler, M., Köhler, T. C., Böhnke, A., Lautenschläger, C., Schmidt, H., Holzhausen, H.-J., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2150 · Cited by 9
Self-citation
TranSNPs: A class of functional SNPs affecting mRNA translation potential revealed by fraction-based allelic imbalance
Valentini, S., Marchioretti, C., Bisio, A., Rossi, A., Zaccara, S., Romanel, A., & Inga, A. (2021) · iScience · doi:10.1016/j.isci.2021.103531 · Cited by 8
Polymorphisms of DNA repair and oxidative stress genes in B-cell lymphoma patients
Fabisiewicz, A., PACHOLEWICZ, K., Paszkiewicz‐Kozik, E., Walewski, J. A., & SIEDLECKI, J. A. (2012) · Biomedical Reports · doi:10.3892/br.2012.31 · Cited by 8
Genotyping of intron 22 inversion of factor VIII gene for diagnosis of hemophilia A by inverse-shifting polymerase chain reaction and capillary electrophoresis
Pan, T.-Y., Wang, C., Shih, C., Wu, H., Chiou, S., & Wu, S. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7969-3 · Cited by 8
Characterization of cancer-associated missense mutations in MDM2
Chauhan, K. M., Ramakrishnan, G., Kollareddy, M., & Martinez, L. A. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1125986 · Cited by 8
Polymorphisms in the p53 pathway genes and micronucleus occurrence in Chinese vinyl chloride-exposed workers
Li, Y., Feng, N.-N., Zhang, G.-H., Wang, Q., Hao, Y.-H., Ya-Nanzhang, Long, C., Li, Y., Brandt‐Rauf, P. W., & Xia, Z.-L. (2013) · International Journal of Occupational Medicine and Environmental Health · doi:10.2478/s13382-013-0155-6 · Cited by 8
Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients
Bauer, M., Kantelhardt, E. J., Stiewe, T., Nist, A., Mernberger, M., Politt, K., Hanf, V., Lantzsch, T., Uleer, C., Peschel, S., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26768 · Cited by 8
Self-citation
Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4
Lucà, R., di Blasio, G., Gallo, D., Monteleone, V., Manni, I., Fici, L., Buttarelli, M., Ciolli, G., Pellegrino, M., Teveroni, E., et al. (2019) · Cancers · doi:10.3390/cancers11091349 · Cited by 8
On-chip ligation of multiplexing probe-pairs for identifying point mutations out of dense SNP loci
Xu, C., Zhou, Y., Deng, J., Deng, X., Guo, Y., Cui, Z., Zhang, Z., Wei, H.-P., Bi, L.-J., & Zhang, X. (2008) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2008.07.009 · Cited by 8
Genetic basis of sex-specific resistance to neuro-oncogenesis in (BDIX × BDIV) F2 rats
Winzen‐Reichert, B., Koelsch, B. U., Fischer, C., & Kindler‐Röhrborn, A. (2009) · Mammalian Genome · doi:10.1007/s00335-009-9226-1 · Cited by 6
Current evidence on the relationship between murine double minute 2 T309G polymorphism and esophageal cancer susceptibility
Chen, B., Xiong, M., & Meng, X.-L. (2014) · Diseases of the Esophagus · doi:10.1111/dote.12240 · Cited by 6
Genetic Polymorphism of MDM2 SNP309 in Patients with Helicobacter Pylori-Associated Gastritis
Tongtawee, T., Dechsukhum, C., Leeanansaksiri, W., Kaewpitoon, S. J., Kaewpitoon, N., Loyd, R. A., Matrakool, L., & Panpimanmas, S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.16.7049 · Cited by 6
Homozygousmdm2SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death
Rosso, M., Polotskaia, A., & Bargonetti, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5312 · Cited by 6
Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients
Stoehr, R., Stoehr, R., Wenners, A. S., Hartmann, A., Bertz, S., Spath, V., Walter, B., Junker, K., Moch, H., Hinze, R., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.15 · Cited by 6
Self-citation
Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance
Herok, M., Wawrzynów, B., Maluszek, M. J., Olszewski, M. B., Żylicz, M., & Żylicz, M. (2021) · Cancers · doi:10.3390/cancers13184501 · Cited by 5
The MDM 2 polymorphism SNP 309 is associated with clinical characteristics and outcome in diffuse large B‐cell lymphoma
Hedström, G., Thunberg, U., Amini, R., Zainuddin, N., Enblad, G., & Berglund, M. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12388 · Cited by 6
Association of Arg72Pro of TP53 and T309G of MDM2 genes polymorphisms with non-small-cell lung cancer in Russians of the Moscow region
Loginov, V. I., Аткарская, М. В., Burdennyy, A. M., Zavarykina, T. M., Kazubskaya, T. P., Nosikov, V. V., Александровна, Б. Э., & Gp, Z. (2014) · Molecular Biology · doi:10.1134/s0026893314010099 · Cited by 5
Primary malignant cardiac tumors: Sex‐related therapy and multidisciplinary approach as a new challenge for the future
Bari, N. D., Ramirez, A. D., & Nasso, G. (2022) · Journal of Cardiac Surgery · doi:10.1111/jocs.16358 · Cited by 5
Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies
Zhao, Y., Yang, X., Hao, X., Pan, X., Zhao, B., Ma, J., Fang, J., & Zhao, M.-H. (2014) · Tumor Biology · doi:10.1007/s13277-014-1886-0 · Cited by 5
Map Making in the 21st Century: Charting Breast Cancer Susceptibility Pathways in Rodent Models
Blackburn, A. C., & Jerry, D. J. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9201-9 · Cited by 5
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
Helwa, R., Gansmo, L. B., Bjørnslett, M., Halle, M. K., Werner, H. M. J., Romundstad, P., Hveem, K., VATTEN, L. J., Dørum, A., Lønning, P. E., et al. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1891291 · Cited by 5
Role of Sex in the Therapeutic Targeting of p53 Circuitry
Mancini, F., Giorgini, L., Teveroni, E., Pontecorvi, A., & Moretti, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698946 · Cited by 5
Li–Fraumeni Syndrome
Malkin, D. M. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_11 · Cited by 5
Therapeutic considerations for Mdm2: not just a one trick pony
Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 6
Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population
Yılmaz, M., Taş, A., Dönmez, G., Kaçan, T., & Siliğ, Y. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.4.1059 · Cited by 5
A pooled analysis of host factors that affect nucleotide excision repair in humans
Zheng, C., Shaposhnikov, S. A., Collins, A. R., Brunborg, G., Azqueta, A., Langie, S. A. S., Dusinka, M., Slyšková, J., Vodička, P., van Schooten, F., et al. (2024) · Mutagenesis · doi:10.1093/mutage/geae028 · Cited by 4
The 40bp Indel Polymorphism rs150550023 in the MDM2 Promoter is Associated with Intriguing Shifts in Gene Expression in the p53-MDM2 Regulatory Hub
Miedl, H., Dietrich, B., Kaserer, K., & Schreiber, M. (2020) · Cancers · doi:10.3390/cancers12113363 · Cited by 5
MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients
Varmazyar, S., Marashi, S. M., Shoja, Z., Tornesello, M. L., Buonaguro, F. M., Shahmahmoodi, S., Naraghi, Z. S., & Jalilvand, S. (2017) · Medical Microbiology and Immunology · doi:10.1007/s00430-016-0491-9 · Cited by 4
Krebsrisiko: Bei Frauen und Männern unterschiedlich ausgeprägt
Kindler‐Röhrborn, A. (2020) · Deutsches Ärzteblatt · doi:10.3238/personko.2020.03.13.02 · Cited by 5
Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients
Gluck, I., Simon, A. J., Catane, R., Pfeffer, R., Schachter, J., Rechavi, G., & Bar, J. (2009) · Melanoma Research · doi:10.1097/cmr.0b013e32832ccd27 · Cited by 4
MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer
Concin, N. (2011) · Oncology Reports · doi:10.3892/or.2011.1560 · Cited by 4
A single nucleotide polymorphism in the Mdm2 promoter and risk of sepsis
Kleiman, D. A., Calvano, J. E., Coyle, S. M., Macor, M., Calvano, S. E., & Lowry, S. F. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.12.049 · Cited by 4
MDM2 T309G polymorphism and esophageal cancer risk: a meta-analysis.
Lei, C., Zhang, W., Fan, J., Qiao, B., Chen, Q., Liu, Q., & Zhao, C. (2015) · Europe PMC (PubMed Central) · Cited by 4
Association between MDM2 SNP309 and endometrial cancer risk
Zou, X., Zhang, Y., Zhang, L., Li, J., Zhu, C., Cheng, Q., Zhou, J., & Chen, Y. (2018) · Medicine · doi:10.1097/md.0000000000013273 · Cited by 4
Is there a relation between Murine double minute 2 T309G polymorphism and lung cancer risk in the Turkish population?
Yilmaz, M., Taş, A., Kaçan, T., Sari, M., & Siliğ, Y. (2017) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2016-0236 · Cited by 3
Sex Disparities in P53 Regulation and Functions: Novel Insights for Personalized Cancer Therapies
Cardano, M., Buscemi, G., & Zannini, L. (2025) · Cells · doi:10.3390/cells14050363 · Cited by 3
Role of mucous cell and p53 protein in gastroprotective activity of methanolic extracts of Ageratum conyzoides Linn in rats
Omotoso, D. R., Ajeigbe, K. O., Owonikoko, M. W., Okwuonu, U. C., Akinola, A. O., Daramola, O. O., Adagboyin, O., & Bienonwu, E. O. (2019) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb2019.16851 · Cited by 3
Li-Fraumeni Syndrome
Ganguly, A. A., & Chen, Z. (2016) · Springer eBooks · doi:10.1007/978-3-319-19674-9_28 · Cited by 2
Association between Single Nucleotide Polymorphisms of Apoptosis and Cell Cycle Control Genes and the Risk of Cancer Development in Chronically Exposed People
Андреевна, Б. Е., Yanishevskaya, M. A., Korechenkova, А. V., & Akleyev, А. V. (2023) · Biology Bulletin · doi:10.1134/s1062359023120038 · Cited by 2
TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome
Bakry, D., & Malkin, D. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_10 · Cited by 2
Lack of an Association between a Functional Polymorphism in the MDM2 Promoter and Breast Cancer in Women in Northeast Iran.
Afshari, Z. T., Nikpoor, A. R., Afshari, J. T., Ganjali, R., Atigh, P. S. G., Shandiz, F. H., & Jamialahmadi, K. (2017) · Europe PMC (PubMed Central) · Cited by 2
Molecular Genetic Markers in Female Reproductive Cancers
Wang, T., Davidson, B., Buckhaults, P., Huang, C., & Pohl, G. (2010) · Journal of Oncology · doi:10.1155/2010/307460 · Cited by 2
MDM2 polymorphisms and cancer risk in basal cell carcinoma
Boyd, M. T., & Vlatković, N. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08375.x · Cited by 2
Basic Science: (May 2006)
Sutherland, R. L., & Scorer, J. (2006) · Breast Cancer Online · doi:10.1017/s1470903106005669 · Cited by 2
Set the Tone:
(2018) · Yale University Press eBooks · doi:10.2307/j.ctvqc6gvg.12 · Cited by 2
A diabetes-induced change of MDM2 SNP309T→G contributes to aberrant retinal angiogenesis
Ma, G., Wu, W., Duan, Y., Yang, Y., Huang, X., Pang, Z., Jiang, H., Ma, J., Yuan, F., Zhou, G., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06695-5 · Cited by 1
Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science
Zhang, R., & Nag, S. A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_16 · Cited by 1
Genetic Polymorphism and Their Role in Lung Cancer
Shaffi, S. M. (2021) · Springer eBooks · doi:10.1007/978-981-33-6699-2_10 · Cited by 1
MDM2 Gene rs2279744 Polymorphism and Breast Cancer Risk: Evidence from Meta-Analysis and Meta-Regression Analysis
Eslami, M. M., Mohammadi, P., Samii, A., Masoudifar, S., Razi, B., Gholampour, J., Jamialahmadi, T., & Sahebkar, A. (2024) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-024-00819-8 · Cited by 1
Association Between Single Nucleotide Polymorphisms of Apoptosis and Cell Cycle Control Genes and the Risk of Cancer Development in Chronically Exposed Persons
Андреевна, Б. Е., Yanishevskaya, M. A., Korechenkova, А. V., & Akleyev, А. V. (2023) · Радиационная биология Радиоэкология · doi:10.31857/s0869803123010046 · Cited by 1
Role of TP53 Mutations in Cancer (An Overview)
Toledo, F. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_5 · Cited by 1
Analysis of TP53, MDM2 and CDKN1A polymorphisms in non-small cell lung cancer patients from the Moscow region
Логинов, В. И., Аткарская, М. В., Burdennyy, A. M., Zavarykina, T. M., Kazubskaya, T. P., Vv, N., Braga, E., & Gp, Z. (2015) · Research · doi:10.13070/rs.en.2.1315 · Cited by 1
Correction: Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
Wiech, M., Olszewski, M. B., Tracz‐Gaszewska, Z., Wawrzynów, B., Żylicz, M., & Żylicz, M. (2013) · PLoS ONE · doi:10.1371/annotation/5f4c812a-79d4-44eb-9890-6a8de45c303b · Cited by 1
The Regulation of the IGF-1/mTOR Pathway by the p53 Tumor Suppressor Gene Functions
Feng, Z., & Levine, A. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_2
Self-citation
Zur Bedeutung des SNP309 des Mdm2-Gens für die CVID und die rheumatoide Arthritis
Müller, M. B. (2008) · Publications of the UdS (Saarland University) · doi:10.22028/d291-21149
Modulation of p53 activities by the prolyl-isomerase PIN1 and the bromodomain protein BRD7
Tocco, F. (2008) · OpenstarTs (Univeristy of Trieste https://www.units.it/)
Modificadores de penetrância de mutações germinativas no gene TP53 em famílias brasileiras com diagnóstico clínico da síndrome de Li-Fraumeni e Li-Fraumeni like: impacto dos polimorfismos intragênicos do TP53 e de genes
Achatz, M. (2008) · doi:10.11606/t.5.2008.tde-29012009-172419
Anàlisi dels mecanismes moleculars implicats en el desenvolupament i progressió dels limfomes de cèl·lula B petita
Fernández, V. (2008) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
CHEK2 1100delC and polygenic susceptibility to breast cancer and colorectal cancer
Wasielewski, M. (2009) · RePub (Erasmus University Rotterdam)
Aurora kinases in solely estrogen-induced oncogenesis: Relation to centrosome amplification and chromosomal instability
Hontz, A. E. (2008) · KU ScholarWorks (University of Kansas)
Original Article MDM2 Expression and Regulation in Prostate Cancer Racial Disparity
Wang, G., Firoz, E. F., Rose, A., Blochin, E., Christos, P. J., Pollens, D., Gerald, W., Oddoux, C., Lee, P., & Osman, I. (2008)
Use of diagnostic and therapeutic biomarkers in personalized oncology based on adult T-cell leukemia/lymphoma research
Hasegawa, H., & Kamihira, S. (2013) · Personalized Medicine Universe · doi:10.1016/j.pmu.2013.05.001
Kliniczne znaczenie polimorfizmu Ser326Cys genu hOGG1 u chorych na niedrobnokomórkowego raka płuca (NDRP)
Drozdowska, A. (2008)
유비퀴틴화에 의한 세포 내 p53의 기능 조절
정진혁, 이준영, 이선미, 최태부, & 안성관 (2009) · KSBB Journal
Evaluation of Mismatch Repair Gene Polymorphisms and their Contribution to Colorectal Cancer and its Subsets
Mrkonjic, M. (2009) · TSpace (University of Toronto)
The Inheritance of p53
Grochola, L. F., Zerón-Medina-Cuairán, J., Repapi, E., Finlayson, A. E. T., Cai, Y., Atwal, G. S., & Bond, G. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_2
Self-citation
A mechanistic study of functional polymorphisms in the MDM2 gene
Solbakken, M. H. (2008) · NORA - Norwegian Open Research Archives
Key Genes in Prostate Cancer Progression: Role of MDM2, PTEN, and TMPRSS2-ERG Fusions
Rathinavelu, A., & Levy, A. (2016) · InTech eBooks · doi:10.5772/64337
Exploring Chromatin-bound MDM2 Functions in Compromised Transcriptional Regulation of p53 Target Genes
Rosso, M. (2015) · CUNY Academic Works (City University of New York)
MDM2 promoter polymorphism (rs2279744) and serum estrogen level are associated with increased risk of epithelial ovarian cancer: A case-control study
Dholariya, S. J., Takodara, S., Mir, R., & Saxena, A. (2018) · International Journal of Clinical Biochemistry and Research · doi:10.18231/2394-6377.2018.0112
Data from Recent Natural Selection Identifies a Genetic Variant in a Regulatory Subunit of Protein Phosphatase 2A that Associates with Altered Cancer Risk and Survival
Grochola, L. F., Vázquez, A., Bond, E. E., Würl, P., Taubert, H. W., Müller, T. H., Levine, A. J., & Bond, G. L. (2023) · doi:10.1158/1078-0432.c.6517599
Self-citation
Data from Recent Natural Selection Identifies a Genetic Variant in a Regulatory Subunit of Protein Phosphatase 2A that Associates with Altered Cancer Risk and Survival
Grochola, L. F., Vázquez, A., Bond, E. E., Würl, P., Taubert, H. W., Müller, T. H., Levine, A. J., & Bond, G. L. (2023) · doi:10.1158/1078-0432.c.6517599.v1
Self-citation
Data from p53 Is Not Required for High CIN to Induce Tumor Suppression
Funk, L. C., Wan, J., Ryan, S. D., Kaur, C., Sullivan, R., Roopra, A., & Weaver, B. A. A. (2023) · doi:10.1158/1541-7786.c.6544973
The MDM2 SNP309 differentially impacts cardiorespiratory fitness in young healthy women and men
Haddadi, G., Lam, B., Akhtar, S., Yavelberg, L., Jamnik, V., & Roudier, E. A. (2024) · European Journal of Applied Physiology · doi:10.1007/s00421-024-05682-1
Optimizing the comet assay to measure DNA damage and repair
Zheng, C. (2025) · Research Publications (Maastricht University) · doi:10.26481/dis.20250422cz
Sentinel Gene Within Cell Territory and Molecular Platforms in Cancer: Methylation Diversity of p53 Gene in Brain Tumors
Mehdipour, P., & Karami, F. (2015) · Springer eBooks · doi:10.1007/978-94-017-9639-2_8
A Case-Only Genome-wide Association Study of Gender- and Age-specific Risk Markers for Childhood Leukemia
Singh, S. K. (2015) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fi15032162
Détermination des fonctions du gène E4F1 dans la voie p53 : caractérisation d’un nouveau niveau de régulation impliquant l’oncoprotéine Mdm2
Schrepfer, E. (2012) · theses.fr (ABES) · doi:10.70675/2a21ac23zee9ez48fbz8b01z9de7c0b09977

Authors: Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., Toppmeyer, D., Offit, K., & Levine, A. J.
Affiliations: Institute for Advanced Study (US)
Rutgers Cancer Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Martin Luther University Halle-Wittenberg (DE)
Universität Ulm (DE)
ORCID: Bond, Gareth L.
Hirshfield, Kim M.
Kirchhoff, Tomas
Robins, Harlan
Taubert, Helge
Toppmeyer, Deborah
Offit, Kenneth
Levine, Arnold J.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2006-05-15
Volume: 66
Issue: 10
Pages: 5104-5110
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-06-0180
OpenAlex: W2131732631
Cited by: 287
References: 50
Citations by year: 2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 21 · 2013: 17 · 2012: 24
FWCI: 18.09
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P01 CA 65930-08, P01CA087497, P01CA065930, P01CA87497., T32CA099946, T32 CA 99946-01)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: MDM2, SNP309, promoter polymorphism, p53 pathway, tumor formation, gender differences in cancer, estrogen, Sp1, nuclear receptors, sporadic cancer, genetic susceptibility
MeSH terms: Adolescent, Adult, Age Factors, Aged, Alleles, Breast Neoplasms, Female, Humans, Male, Middle Aged, Neoplasms, Hormone-Dependent, Sarcoma, Case-Control Studies, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Ductal, Breast, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks